GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lorigerlimab   Click here for help

GtoPdb Ligand ID: 14407

Synonyms: MGD-019 | MGD019
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lorigerlimab (MGD019) is a tetravalent bispecific IgG4 antibody that simultaneously targets CTLA-4 and PD-1, developed by MacroGenics using DART® technology [1]. It was proposed to reverse the immunosuppressive and immune evasion activities of these two immune checkpoint proteins and thereby enhance the efficacy of tumour-infiltrating lymphocytes in the tumour microenvironment.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
The PD-1 and CTLA-4 immune checkpoint proteins are co-expressed by tumour-infiltrating lymphocytes and act to suppress activity of immune cells in the tumour microenvironment. Simultaneously blocking both antigens with one antibody is proposed to boost the anti-tumour immune response whilst minimising effects on healthy tissues.